AstraZeneca Gets Orphan Drug Designation for Lung Disease Treatment
March 18 2019 - 3:38AM
Dow Jones News
By Adam Clark
AstraZeneca PLC (AZN.LN) said Monday that the U.S. Food &
Drug Administration has granted orphan drug designation for
potential lung-disease treatment saracatinib.
The drug company said saracatinib has completed phase 1
development as a treatment for idiopathic pulmonary fibrosis, a
chronic and normally fatal disease that affects around 100,000
people in the U.S.
"IPF is a recent addition to our respiratory research strategy
and we are interested to see whether saracatinib could be a useful
approach for the treatment of this intractable disease," Mene
Pangalos, executive vice-president at AstraZeneca, said.
Write to Adam Clark at adam.clark@dowjones.com;
@AdamDowJones
(END) Dow Jones Newswires
March 18, 2019 03:23 ET (07:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024